January 5, 2011

Positive Phase II Results with BSI-201 (Iniparib) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine

 

Positive Phase II Results with BSI-201 (Iniparib) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine

Paris, France – January 5, 2011 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine (NEJM) published the final Phase II data for the investigational drug BSI-201 (iniparib*) demonstrating significant clinical benefit in women with metastatic triple negative breast cancer (mTNBC) when BSI-201 (iniparib) was administered in combination with chemotherapy agents gemcitabine/carboplatin. Although not a prespecified endpoint, overall survival also was significantly increased in women who received BSI-201 (iniparib).